Decision on IPR: Oct 31, 2018
|
AIA Review
|
Filing Date
|
Institution Date
|
Petitioner
|
US Patent
|
Respondent
|
Final Written Decision
|
|
IPR2017-01168
|
04/28/2017
|
11/06/2017
|
Pfizer, Inc.
|
8,821,873
|
Biogen Inc.
|
Claims 1–5 are unpatentable
|
US 8,821,873 (Biogen Inc;
Exp: Jul 28, 2020)
1. A method of treating a patient with diffuse large cell lymphoma
comprising administering anti-CD20 antibody and chemotherapy to the patient,
wherein the patient is >60 years old, wherein the chemotherapy comprises
CHOP (cyclophosphamide, hydroxydaunorubicin/doxorubicin, vincristine, and
prednisone/prednisolone), and wherein the anti-CD20 antibody is administered to
the patient in combination with stem cell transplantation regimen.
5. A method of treating a patient with diffuse large cell
lymphoma comprising administering rituximab and CHOP (cyclophosphamide, hydroxydaunorubicin/doxorubicin,
vincristine, and prednisone/prednisolone) to the patient, in combination with
stem cell transplantation, wherein the patient is >60 years old.
No comments:
Post a Comment